toripalimab

Toripalimab is a humanized IgG4 monoclonal antibody that functions as an immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor. By binding to PD-1, it blocks its interaction with ligands PD-L1 and PD-L2, thereby preventing the inhibition of T-cell activation and restoring anti-tumor immune responses. Toripalimab has demonstrated high affinity for PD-1 and promotes robust Th1-type immune responses. It is primarily indicated for the treatment of nasopharyngeal carcinoma (NPC), both as monotherapy in patients with recurrent or metastatic disease after platinum-based chemotherapy, and in combination with gemcitabine and cisplatin as first-line therapy for metastatic or recurrent locally advanced NPC. The drug was first approved in China for melanoma and received FDA approval in October 2023 for NPC.

Brand names

Loqtorzi

Other names

toripalimab-tpzi